Clinical Trial Detail

NCT ID NCT02278133
Title Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Cetuximab + Encorafenib + LGK974

Age Groups: adult

Additional content available in CKB BOOST